Podcast
Play an AI-generated podcast conversation about this lesson
Questions and Answers
What is the primary challenge in individualizing therapy for patients?
What is the primary challenge in individualizing therapy for patients?
- Patients' heterogeneous responses to treatment (correct)
- Radiopharmaceutical agents' limited availability
- Lack of effective chemotherapy regimens
- Inability to assess treatment response rapidly
Why is it insufficient to rely solely on tumor volume changes to evaluate response to antitumor therapy?
Why is it insufficient to rely solely on tumor volume changes to evaluate response to antitumor therapy?
- Patients may develop toxicity and side effects before changes are evident (correct)
- Radiopharmaceutical agents are not effective in predicting response
- Tumor volume changes are difficult to measure
- Changes in tumor volume occur too slowly
What is the benefit of using radiopharmaceutical agents like Gallium or FDG in evaluating response to therapy?
What is the benefit of using radiopharmaceutical agents like Gallium or FDG in evaluating response to therapy?
- They can predict response to treatment as early as after 1-3 cycles of chemotherapy (correct)
- They are not effective in detecting response to chemotherapy
- They can only be used after multiple cycles of chemotherapy
- They are only effective in detecting response in lymphoma
What is the purpose of evaluating response to therapy?
What is the purpose of evaluating response to therapy?
Signup and view all the answers
What is a limitation of using CT or MRI studies to evaluate response to therapy?
What is a limitation of using CT or MRI studies to evaluate response to therapy?
Signup and view all the answers
What is demonstrated in the follow-up study (b) in a patient with non-Hodgkin's lymphoma?
What is demonstrated in the follow-up study (b) in a patient with non-Hodgkin's lymphoma?
Signup and view all the answers
